ClaripulseClaripulse
MAUDE LookupResourcesBlog
LoginGet Early Access
ClaripulseClaripulse

Product

MAUDE LookupDashboard

Guides

FDA MAUDE DatabasePost-Market SurveillanceSignal Detection

Learn

BlogResourcesWhy Claripulse?

Legal

Privacy PolicyTerms of Service

This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified — do not attempt re-identification. © 2026 Claripulse.

Back to Structural Heart
MAUDE LookupStructural HeartSAPIEN 3 Ultra delivery system

SAPIEN 3 Ultra delivery system Adverse Events: FDA MAUDE Data

Edwards Lifesciences LLC · Transcatheter Aortic Valve (TAVR) · First cleared Jun 2015

Total Reports

348

Reports (30d)

0

Active Signals

1

Open Recalls

0

Monthly Report Volume
Event Type Breakdown

What the reports describe · Claripulse analysis

Most commonly reported problems

1

Delivery System Failure During Procedure

ultra, sheath, delivery, esheath, balloon

1

reports

2

Valve Explantation 4 Years Post-Implant

valve aortic, aortic position, registry, months, ultra

1

reports

3

Valve-in-Valve Procedure for Stenosis

ultra, clinical specialist, valve valve, field, field clinical

1

reports

Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.

Detection

Active safety signals

Disproportionate reportinghigh

Evidence

Related research

In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry.

Saia F, et al. · 2020

One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry.

Cannata S, et al. · EuroIntervention · 2023

Routine post-dilatation at nominal volume to optimise the expansion of balloon-expandable valves: the DOUBLE-TAP study

Ali Husain, et al. · EuroIntervention · 2025

Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study

Giulia Nardi, et al. · EuroIntervention · 2022

Feasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy

Kendra J. Grubb, et al. · EuroIntervention · 2023

Citations indexed from PubMed.

Keep exploring

Related devices in Structural

MitraClip

ABBOTT VASCULAR INC. · 17,746 reports

→

Edwards SAPIEN 3 Ultra Transcatheter Heart Valve

Edwards Lifesciences LLC · 13,096 reports

→

Evolut FX

MEDTRONIC, INC. · 11,918 reports

→

Evolut PRO

MEDTRONIC, INC. · 7,401 reports

→

CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL BIOPROSTHESIS - AORTIC

Edwards Lifesciences LLC · 6,040 reports

→

CoreValve Evolut

MEDTRONIC, INC. · 4,236 reports

→

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 1 active signal detected right now.

Get Early Access

Understanding this data

What FDA MAUDE data does and does not tell you

How these reports are filed, why raw counts mislead, and the limits to know before drawing conclusions.

→

How a safety signal is detected

What the "Active Signals" count above means and the methods that separate a real signal from noise.

→
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.